ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases

Manfred Rieger, Pier Mannuccio Mannucci, Johanna A. Kremer Hovinga, Andrea Herzog, Gabi Gerstenbauer, Christian Konetschny, Klaus Zimmermann, Inge Scharrer, Flora Peyvandi, Miriam Galbusera, Giuseppe Remuzzi, Martina Böhm, Barbara Plaimauer, Bernhard Lämmle, Friedrich Scheiflinger

Research output: Contribution to journalArticle

201 Citations (Scopus)

Abstract

Autoantibodies neutralizing human ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motif), the metalloprotease that physiologically cleaves von Willebrand factor, are a major cause of severe deficiency of the protease and of acquired thrombotic thrombocytopenic purpura (TTP). We evaluated prevalence of anti-ADAMTS13 antibodies in 59 patients with thrombotic microangiopathies (TMAs) and in 160 patients with immunologic or thrombocytopenic diseases different from TTP, using an enzyme-linked immunosorbent assay (ELISA). Immunoglobulin G (IgG) antibodies directed against ADAMTS13 were found in 97% of untreated patients with acute acquired TMA who had plasma levels of ADAMTS13 activity below 10%. The corresponding prevalence of IgM antibodies was 11%. In contrast, anti-ADAMTS13 antibodies of G or M isotypes were detected in 20% of patients with TMA with ADAMTS13 activity above 10%. The ELISA was more sensitive than the standard functional inhibitor assay for detecting antibodies against ADAMTS13. Patients with thrombocytopenia from various causes (n = 50), systemic lupus erythematosus (SLE; n = 40), and the antiphospholipid antibody syndrome (APS; n = 55) had prevalences of IgG antibodies of 8%, 13%, and 5% respectively, only slightly higher than the prevalence in 111 healthy donors (4%). A rather high prevalence of anti-ADAMTS13 IgM antibodies was found in patients with SLE and APS (18% each). The clinical significance of IgM antibodies in these groups is unclear. In conclusion, the ELISA method detected anti-ADAMTS13 IgG antibodies in a very large proportion of patients with acquired TMA associated with severe ADAMTS13 deficiency, and was more sensitive than the inhibitor assay.

Original languageEnglish
Pages (from-to)1262-1267
Number of pages6
JournalBlood
Volume106
Issue number4
DOIs
Publication statusPublished - Aug 15 2005

Fingerprint

Thrombotic Microangiopathies
Autoantibodies
Antibodies
Assays
Immunosorbents
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Metalloproteases
Immunoglobulin M
Anti-Idiotypic Antibodies
Thrombospondin 1
Disintegrins
Thrombotic Thrombocytopenic Purpura
Enzymes
Antiphospholipid Syndrome
von Willebrand Factor
Thrombocytopenia
Systemic Lupus Erythematosus
Antiphospholipid Antibodies
Peptide Hydrolases

ASJC Scopus subject areas

  • Hematology

Cite this

Rieger, M., Mannucci, P. M., Kremer Hovinga, J. A., Herzog, A., Gerstenbauer, G., Konetschny, C., ... Scheiflinger, F. (2005). ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 106(4), 1262-1267. https://doi.org/10.1182/blood-2004-11-4490

ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. / Rieger, Manfred; Mannucci, Pier Mannuccio; Kremer Hovinga, Johanna A.; Herzog, Andrea; Gerstenbauer, Gabi; Konetschny, Christian; Zimmermann, Klaus; Scharrer, Inge; Peyvandi, Flora; Galbusera, Miriam; Remuzzi, Giuseppe; Böhm, Martina; Plaimauer, Barbara; Lämmle, Bernhard; Scheiflinger, Friedrich.

In: Blood, Vol. 106, No. 4, 15.08.2005, p. 1262-1267.

Research output: Contribution to journalArticle

Rieger, M, Mannucci, PM, Kremer Hovinga, JA, Herzog, A, Gerstenbauer, G, Konetschny, C, Zimmermann, K, Scharrer, I, Peyvandi, F, Galbusera, M, Remuzzi, G, Böhm, M, Plaimauer, B, Lämmle, B & Scheiflinger, F 2005, 'ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases', Blood, vol. 106, no. 4, pp. 1262-1267. https://doi.org/10.1182/blood-2004-11-4490
Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005 Aug 15;106(4):1262-1267. https://doi.org/10.1182/blood-2004-11-4490
Rieger, Manfred ; Mannucci, Pier Mannuccio ; Kremer Hovinga, Johanna A. ; Herzog, Andrea ; Gerstenbauer, Gabi ; Konetschny, Christian ; Zimmermann, Klaus ; Scharrer, Inge ; Peyvandi, Flora ; Galbusera, Miriam ; Remuzzi, Giuseppe ; Böhm, Martina ; Plaimauer, Barbara ; Lämmle, Bernhard ; Scheiflinger, Friedrich. / ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. In: Blood. 2005 ; Vol. 106, No. 4. pp. 1262-1267.
@article{df9469619d334b5eba4e910835e9b9b7,
title = "ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases",
abstract = "Autoantibodies neutralizing human ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motif), the metalloprotease that physiologically cleaves von Willebrand factor, are a major cause of severe deficiency of the protease and of acquired thrombotic thrombocytopenic purpura (TTP). We evaluated prevalence of anti-ADAMTS13 antibodies in 59 patients with thrombotic microangiopathies (TMAs) and in 160 patients with immunologic or thrombocytopenic diseases different from TTP, using an enzyme-linked immunosorbent assay (ELISA). Immunoglobulin G (IgG) antibodies directed against ADAMTS13 were found in 97{\%} of untreated patients with acute acquired TMA who had plasma levels of ADAMTS13 activity below 10{\%}. The corresponding prevalence of IgM antibodies was 11{\%}. In contrast, anti-ADAMTS13 antibodies of G or M isotypes were detected in 20{\%} of patients with TMA with ADAMTS13 activity above 10{\%}. The ELISA was more sensitive than the standard functional inhibitor assay for detecting antibodies against ADAMTS13. Patients with thrombocytopenia from various causes (n = 50), systemic lupus erythematosus (SLE; n = 40), and the antiphospholipid antibody syndrome (APS; n = 55) had prevalences of IgG antibodies of 8{\%}, 13{\%}, and 5{\%} respectively, only slightly higher than the prevalence in 111 healthy donors (4{\%}). A rather high prevalence of anti-ADAMTS13 IgM antibodies was found in patients with SLE and APS (18{\%} each). The clinical significance of IgM antibodies in these groups is unclear. In conclusion, the ELISA method detected anti-ADAMTS13 IgG antibodies in a very large proportion of patients with acquired TMA associated with severe ADAMTS13 deficiency, and was more sensitive than the inhibitor assay.",
author = "Manfred Rieger and Mannucci, {Pier Mannuccio} and {Kremer Hovinga}, {Johanna A.} and Andrea Herzog and Gabi Gerstenbauer and Christian Konetschny and Klaus Zimmermann and Inge Scharrer and Flora Peyvandi and Miriam Galbusera and Giuseppe Remuzzi and Martina B{\"o}hm and Barbara Plaimauer and Bernhard L{\"a}mmle and Friedrich Scheiflinger",
year = "2005",
month = "8",
day = "15",
doi = "10.1182/blood-2004-11-4490",
language = "English",
volume = "106",
pages = "1262--1267",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases

AU - Rieger, Manfred

AU - Mannucci, Pier Mannuccio

AU - Kremer Hovinga, Johanna A.

AU - Herzog, Andrea

AU - Gerstenbauer, Gabi

AU - Konetschny, Christian

AU - Zimmermann, Klaus

AU - Scharrer, Inge

AU - Peyvandi, Flora

AU - Galbusera, Miriam

AU - Remuzzi, Giuseppe

AU - Böhm, Martina

AU - Plaimauer, Barbara

AU - Lämmle, Bernhard

AU - Scheiflinger, Friedrich

PY - 2005/8/15

Y1 - 2005/8/15

N2 - Autoantibodies neutralizing human ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motif), the metalloprotease that physiologically cleaves von Willebrand factor, are a major cause of severe deficiency of the protease and of acquired thrombotic thrombocytopenic purpura (TTP). We evaluated prevalence of anti-ADAMTS13 antibodies in 59 patients with thrombotic microangiopathies (TMAs) and in 160 patients with immunologic or thrombocytopenic diseases different from TTP, using an enzyme-linked immunosorbent assay (ELISA). Immunoglobulin G (IgG) antibodies directed against ADAMTS13 were found in 97% of untreated patients with acute acquired TMA who had plasma levels of ADAMTS13 activity below 10%. The corresponding prevalence of IgM antibodies was 11%. In contrast, anti-ADAMTS13 antibodies of G or M isotypes were detected in 20% of patients with TMA with ADAMTS13 activity above 10%. The ELISA was more sensitive than the standard functional inhibitor assay for detecting antibodies against ADAMTS13. Patients with thrombocytopenia from various causes (n = 50), systemic lupus erythematosus (SLE; n = 40), and the antiphospholipid antibody syndrome (APS; n = 55) had prevalences of IgG antibodies of 8%, 13%, and 5% respectively, only slightly higher than the prevalence in 111 healthy donors (4%). A rather high prevalence of anti-ADAMTS13 IgM antibodies was found in patients with SLE and APS (18% each). The clinical significance of IgM antibodies in these groups is unclear. In conclusion, the ELISA method detected anti-ADAMTS13 IgG antibodies in a very large proportion of patients with acquired TMA associated with severe ADAMTS13 deficiency, and was more sensitive than the inhibitor assay.

AB - Autoantibodies neutralizing human ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motif), the metalloprotease that physiologically cleaves von Willebrand factor, are a major cause of severe deficiency of the protease and of acquired thrombotic thrombocytopenic purpura (TTP). We evaluated prevalence of anti-ADAMTS13 antibodies in 59 patients with thrombotic microangiopathies (TMAs) and in 160 patients with immunologic or thrombocytopenic diseases different from TTP, using an enzyme-linked immunosorbent assay (ELISA). Immunoglobulin G (IgG) antibodies directed against ADAMTS13 were found in 97% of untreated patients with acute acquired TMA who had plasma levels of ADAMTS13 activity below 10%. The corresponding prevalence of IgM antibodies was 11%. In contrast, anti-ADAMTS13 antibodies of G or M isotypes were detected in 20% of patients with TMA with ADAMTS13 activity above 10%. The ELISA was more sensitive than the standard functional inhibitor assay for detecting antibodies against ADAMTS13. Patients with thrombocytopenia from various causes (n = 50), systemic lupus erythematosus (SLE; n = 40), and the antiphospholipid antibody syndrome (APS; n = 55) had prevalences of IgG antibodies of 8%, 13%, and 5% respectively, only slightly higher than the prevalence in 111 healthy donors (4%). A rather high prevalence of anti-ADAMTS13 IgM antibodies was found in patients with SLE and APS (18% each). The clinical significance of IgM antibodies in these groups is unclear. In conclusion, the ELISA method detected anti-ADAMTS13 IgG antibodies in a very large proportion of patients with acquired TMA associated with severe ADAMTS13 deficiency, and was more sensitive than the inhibitor assay.

UR - http://www.scopus.com/inward/record.url?scp=23744486523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744486523&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-11-4490

DO - 10.1182/blood-2004-11-4490

M3 - Article

C2 - 15890682

AN - SCOPUS:23744486523

VL - 106

SP - 1262

EP - 1267

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -